Chymostatin
Need Assistance?
  • US & Canada:
    +
  • UK: +

Chymostatin

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Chymostatin is a bioactive peptide that acts as a protease inhibitor with selectivity for chymotryptase-like serine proteases. It potently inhibits chymotrypsin and chymase, but it cannot block the activity of cathepsins, papain, and leukocyte elastase effectively. It doesn't have effect on trypsin, thrombin, plasmin, pepsin, and kallikrein.

Category
Peptide Inhibitors
Catalog number
BAT-015141
CAS number
9076-44-2
Molecular Formula
CxHyN7O6
Molecular Weight
607.7
Chymostatin
IUPAC Name
(2S)-2-[[(1S)-1-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-2-[[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-phenylpropan-2-yl]amino]pentan-2-yl]amino]-2-oxoethyl]carbamoylamino]-3-phenylpropanoic acid
Synonyms
[(S)-1-Carboxy-2-phenylethyl]-carbamoyl-a-[2-amidohexahydro-4(S)-pyrimidyl]-(S)-glycyl-[A= Leu B=Val C=Ile]-phenylalaninal (Mixture)
Appearance
Crystalline Solid
Purity
≥95% (a mixture of A, B, C)
Storage
Store at -20°C
Solubility
Soluble in DMSO (10 mM), Glacial Acetic Acid (10 mg/ml), Water (Slightly); Insoluble in Ethyl Acetate, Butyl Acetate, Ether, Hexane, Petroleum Ether
Application
Serine Proteinase Inhibitors
InChI
InChI=1S/C31H41N7O6/c1-19(2)15-24(27(40)34-22(18-39)16-20-9-5-3-6-10-20)35-28(41)26(23-13-14-33-30(32)36-23)38-31(44)37-25(29(42)43)17-21-11-7-4-8-12-21/h3-12,18-19,22-26H,13-17H2,1-2H3,(H,34,40)(H,35,41)(H,42,43)(H3,32,33,36)(H2,37,38,44)/t22-,23?,24-,25-,26-/m0/s1
InChI Key
MRXDGVXSWIXTQL-HYHFHBMOSA-N
Canonical SMILES
CC(C)CC(C(=O)NC(CC1=CC=CC=C1)C=O)NC(=O)C(C2CCN=C(N2)N)NC(=O)NC(CC3=CC=CC=C3)C(=O)O
1.Isolation and characterization of a serine protease-producing marine bacterium Marinomonas arctica PT-1.
Yoo AY1, Park JK2. Bioprocess Biosyst Eng. 2016 Feb;39(2):307-14. doi: 10.1007/s00449-015-1514-4. Epub 2015 Dec 1.
A serine protease-producing marine bacterial strain named as PT-1 was isolated and identified as a family of Marinomonas arctica, based on molecular characterization of 16S rRNA gene sequence, phylogenetic tree, and fatty acid composition analyses. Optimized culture conditions for growth of the bacterium PT-1 and production of protease (ProA) were determined to be pH 8.0 in the presence of 5 % NaCl, at 37 °C during 24 h of incubation in the presence of 1.0 % skim milk. The molecular weight of the purified ProA was estimated to be 63-kDa as a major band by SDS-PAGE. We were intrigued to find that the activity of ProA was not inhibited by pepstatin A, chymostatin, and leupeptin known as inhibitors for cysteine protease. However, phenylmethylsulfonyl fluoride (PMSF) completely inhibited protease activity, suggesting that the ProA is like a serine protease. To the best of our knowledge, this is the first report on serine protease of Marinomonas species.
2.THE AUTOCRINE ROLE OF TRYPTASE IN PRESSURE OVERLOAD-INDUCED MAST CELL ACTIVATION, CHYMASE RELEASE AND CARDIAC FIBROSIS.
Li J1, Jubair S1, Levick SP2, Janicki JS1. IJC Metab Endocr. 2016 Mar 1;10:16-23. Epub 2015 Nov 24.
BACKGROUND: Cardiac mast cell (MC) proteases, chymase and tryptase, increase proliferation and collagen synthesis in cultured cardiac fibroblasts. However, the question as to why preventing individually the actions of either protease prevents fibrosis when both are released upon MC activation remains unanswered. Since tryptase has the ability to activate MCs in noncardiac tissues via the protease-activated receptor-2 (PAR-2), there is the possibility that its, in vivo, fibrotic role is due to its ability to induce MC degranulation thereby amplifying the release of chymase.
3.A chymotrypsin from the Digestive Tract of California Spiny Lobster, Panulirus interruptus: Purification and Biochemical Characterization.
Bibo-Verdugo B1, Rojo-Arreola L, Navarrete-del-Toro MA, García-Carreño F. Mar Biotechnol (NY). 2015 Aug;17(4):416-27. doi: 10.1007/s10126-015-9626-z. Epub 2015 Apr 16.
A chymotrypsin was purified from the gastric juice of California spiny lobster (Panulirus interrutpus), using preparative electrophoresis and affinity chromatography on agarose-p-aminobenzamidine. The molecular mass was estimated by polyacrylamide gel electrophoresis (SDS-PAGE) under denaturing conditions to be 28 kDa. Chymotrypsin activity was totally inhibited by phenylmethylsulfonyl fluoride (PMSF) and chymostatin. Lobster chymotrypsin had optimal pH 7.0-8.0 and temperature of 55 °C. The enzyme is highly stable under a wide range of pH (retaining up to 80 % of activity after 1 h of incubation at pH 3.0, 5.0, and 12.0), showing higher stability at pH 8.0, and was inactivated after 20 min at 55 °C. Lobster chymotrypsin was able to hydrolyze protein substrates at as low as pH 3.0. These results are consistent with the findings of enzyme stability. Activity was assessed after incubation of enzyme with different organic solvents (in the range of 10-50 %); when tested in the presence of acetone, ethanol, propanol, and butanol, lobster chymotrypsin residual activity was >80 %; whereas in the presence of dimethyl sulfoxide (DMSO) and toluene, lobster chymotrypsin residual activity was <80 %.
4.Structural and enzymatic characterization of a host-specificity determinant from Salmonella.
Kohler AC1, Spanò S2, Galán JE2, Stebbins CE1. Acta Crystallogr D Biol Crystallogr. 2014 Feb;70(Pt 2):384-91. doi: 10.1107/S1399004713028393. Epub 2014 Jan 29.
GtgE is an effector protein from Salmonella Typhimurium that modulates trafficking of the Salmonella-containing vacuole. It exerts its function by cleaving the Rab-family GTPases Rab29, Rab32 and Rab38, thereby preventing the delivery of antimicrobial factors to the bacteria-containing vacuole. Here, the crystal structure of GtgE at 1.65 Å resolution is presented, and structure-based mutagenesis and in vivo infection assays are used to identify its catalytic triad. A panel of cysteine protease inhibitors were examined and it was determined that N-ethylmaleimide, antipain and chymostatin inhibit GtgE activity in vitro. These findings provide the basis for the development of novel therapeutic strategies to combat Salmonella infections.
Online Inquiry
Verification code
Inquiry Basket